About: The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial
Creator	Coenjaerts, F Bolkenbaas, M Bonten, M Grobbee, D Huijts, S Van Werkhoven, C
Source	Elsevier; Medline; PMC
abstract	OBJECTIVES: Our objective was to evaluate whether vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) prevents the incidence of community-acquired pneumonia (CAP) caused by influenza (influenza-associated CAP, IA-CAP) or other respiratory viruses in the elderly. METHODS: This analysis was part of the Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA); a double blind, randomized, placebo-controlled trial in 84 496 immunocompetent individuals aged ≥65 years. CAP was defined by clinical and radiological criteria, and oropharyngeal swabs were collected from all individuals referred to a sentinel centre with a clinical suspicion of pneumonia. Presence of influenza A and B, parainfluenza 1, 2, 3 and 4, human adeno-, boca-, corona-, metapneumo-, rhino- and respiratory syncytial viruses was determined by real-time PCR. RESULTS: Of 3209 episodes of suspected pneumonia, viral aetiology was tested in 2917 and proportions with influenza virus, human metapneumovirus and respiratory syncytial virus were 4.6%, 2.5% and 3.1%, respectively. There were 1653 oropharyngeal swabs for PCR testing available from 1814 episodes that fulfilled criteria for CAP, yielding 23 first episodes of IA-CAP in the PCV13 and 35 in the in placebo group—vaccine efficacy for IA-CAP of 34.4% (95% CI –11.1% to 61.2%; p 0.117). Annual influenza vaccination was received by 672 (87.2%) in the PCV13 group and 719 (87.7%) in the placebo group of the confirmed CAP cases. CONCLUSION: In a randomized study of 84 496 elderly individuals with a high uptake of influenza vaccination, PCV13 was not associated with a statistically significant reduction of influenza or virus-associated CAP. Overall incidence of non-influenza viral pneumonia was low.
has issue date	2017-10-16(xsd:dateTime)
bibo:doi	10.1016/j.cmi.2017.10.006
bibo:pmid	29050992
has license	no-cc
sha1sum (hex)	ebb0923ff2b6a4d69e60af7b5fa8fa66a0d8e07e
schema:url	https://doi.org/10.1016/j.cmi.2017.10.006
resource representing a document's title	The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial
has PubMed Central identifier	PMC7129545
has PubMed identifier	29050992
schema:publication	Clin Microbiol Infect
resource representing a document's body	covid:ebb0923ff2b6a4d69e60af7b5fa8fa66a0d8e07e#body_text
is schema:about of	named entity 'randomized' named entity 'vaccination' named entity 'parainfluenza' named entity 'Adults' named entity 'Pneumonia' named entity 'This' named entity 'human metapneumovirus' named entity 'ANALYSIS' named entity 'ELDERLY' named entity 'VIRUS' named entity 'REFERRED TO' named entity 'BOCA' named entity '4.6' named entity 'ADULTS' named entity 'E11.1' named entity '2.5' named entity 'INFLUENZA VIRUS' named entity 'OVERALL' named entity 'OBJECTIVES' named entity 'EVALUATE' named entity 'INDIVIDUALS' named entity 'VACCINATION' named entity 'INFECT' named entity 'CLIN' named entity 'PNEUMONIA' named entity 'AVAILABLE' named entity 'DOUBLE BLIND' named entity 'PRESENCE OF' named entity 'SENTINEL' named entity 'HUMAN METAPNEUMOVIRUS' named entity 'TESTED' named entity 'ANALYSIS' named entity 'INCIDENCE' named entity '2018' named entity 'PLACEBO-CONTROLLED TRIAL' named entity 'IMMUNOCOMPETENT' named entity 'LOW' named entity '2887' named entity 'RESPIRATORY SYNCYTIAL VIRUSES' named entity 'SWABS' named entity 'NON-' named entity 'SUSPICION' named entity 'CONCLUSION' named entity 'INDIVIDUALS AGED' named entity 'ASSOCIATED' named entity 'OUR' named entity 'EFFICACY' named entity '672' named entity 'RESULTS' named entity 'CAUSED BY' named entity 'ADENO' named entity 'CORONA' named entity 'ELDERLY INDIVIDUALS' named entity '496' named entity 'PCR' named entity 'DETERMINED BY' named entity 'GROUP' named entity '61.2' named entity 'PLACEBO' named entity 'INFLUENZA' named entity 'DEFINED' named entity 'PCV13' named entity 'INFLUENZA A' named entity 'IMPACT' named entity '3.1' named entity 'EPISODES' named entity 'INFLUENZA VACCINATION' named entity 'OBJECTIVE' named entity 'TRIAL' named entity 'PNEUMOCOCCAL CONJUGATE VACCINATION' named entity 'COMMUNITY-ACQUIRED PNEUMONIA' named entity 'S.M' named entity 'YEARS' named entity 'CASES' named entity 'PREVENTS' named entity 'ASSOCIATED WITH'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software